About CrossPoint Therapeutics
CrossPoint Therapeutics is a company based in Hwaseong (South Korea) founded in 2022 by Tae-Erk Kim. CrossPoint Therapeutics has raised $2.39 million across 1 funding round from investors including Kudos Ventures. CrossPoint Therapeutics offers products and services including Stealth-Body Technology. CrossPoint Therapeutics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Hwaseong, South Korea
- Founders Tae-Erk Kim
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.39 M (USD)
in 1 rounds
-
Latest Funding Round
$2.39 M (USD), Seed
Mar 30, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CrossPoint Therapeutics
CrossPoint Therapeutics offers a comprehensive portfolio of products and services, including Stealth-Body Technology.
Proprietary system for antibodies with reduced Fc-effector functions to limit toxicity.
Funding Insights of CrossPoint Therapeutics
CrossPoint Therapeutics has successfully raised a total of $2.39M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.39 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CrossPoint Therapeutics
CrossPoint Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Kudos Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for CrossPoint Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CrossPoint Therapeutics
Investment portfolio details for CrossPoint Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CrossPoint Therapeutics
Detailed financials for CrossPoint Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crosspoint Therapeutics Comparisons
Peer comparison for CrossPoint Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CrossPoint Therapeutics
CrossPoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of CrossPoint Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crosspoint Therapeutics
Complete news archive for CrossPoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CrossPoint Therapeutics
CrossPoint Therapeutics was founded in 2022 and raised its 1st funding round 4 years after it was founded.
CrossPoint Therapeutics is headquartered in Hwaseong, South Korea. It is registered at Hwaseong, Gyeonggi Province, South Korea.
Tae-Erk Kim is the current CEO of CrossPoint Therapeutics. They have also founded this company.
CrossPoint Therapeutics is a funded company, having raised a total of $2.39M across 1 funding round to date.
CrossPoint Therapeutics was founded in 2022 and is based in Hwaseong, South Korea. Immunotherapies for cancer treatment are developed through its Stealth-Body technology and Fc inert antibody platform. Antibody therapies include CPP-001 for protein delivery, CPS-001 for small molecule delivery, and CPR-001 for gene delivery. Operations focus on advancing these modalities in the biotechnology sector to address oncology needs.
CrossPoint Therapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.
CrossPoint Therapeutics offers Stealth-Body Technology.
CrossPoint Therapeutics has 1 investor. Key investors include Kudos Ventures.